Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
This feature explores evolving management strategies for bone sarcomas, highlighting multidisciplinary treatment approaches ...
In this phase 3 trial, researchers aimed to characterize the clinical characteristics, treatment approaches, and outcomes of patients with metastatic non-rhabdomyosarcoma soft tissue sarcoma and to ...
Health experts have underlined that soft tissue sarcomas, a rare and complex group of cancers, require precise diagnosis, ...
The domestic patent for Keytruda, the world’s top-selling medicine by annual sales, is scheduled to expire in 2028. A fierce ...
During a live event, Brittany Siontis, MD, a sarcoma oncologist at Mayo Clinic, and participants examined how to choose between the systemic options for progressive desmoid tumors ...
A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit ...
Natera NTRA announced that its molecular residual disease (MRD) test, Signatera, received certification as a Class C device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results